Find Magnetic Resonance Brain stock video, 4K footage, and other HD footage from iStock. Get higher quality Magnetic Resonance Brain content, for less—All of our 4K video clips are the same price as ...

Video Back Videos home Signature collection Essentials collection Artificial Intelligence ...

(MENAFN- GlobeNewsWire - Nasdaq) Phase 2b study evaluating diagnostic performance of 18F-RAD101 for suspected recurrent brain metastases from solid tumors of different origins SYDNEY, April 28 ...

SYDNEY, April 28, 2025 (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, Nasdaq: RADX, “Radiopharm” or the “Company”), a clinical-stage biopharmaceutical company focused on developing ...

Telix Pharmaceuticals has pointed to “promising efficacy” for its radiation therapy in a small, single arm study of patients with brain cancer. The phase 2 Ipax-Linz trial enrolled eight ...

Telix Pharmaceuticals Ltd.’s glioblastoma theranostic, TLX-101, is showing promising overall survival in a phase II trial in recurrent high-grade glioma. The targeted radiation therapy, combined with ...

Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial ...

ALX Oncology Holdings Inc. (ALXO),announced Friday that its Phase 2 ASPEN-03 and ASPEN-04 trials evaluating evorpacept in combination with Merck's KEYTRUDA or pembrolizumab in advanced head and ...

(RTTNews) - Telix Pharmaceuticals Limited (TLX, TLX.AX) announces preliminary results from the Phase 2 IPAX-Linz study of TLX101 (131I-iodofalan) in recurrent high-grade glioma (brain cancer ...

Currently, there is no FDA approved right heart contrast agent.” said Morgan Evans, CEO of Agitated Solutions. “This IND clearance is a significant milestone, allowing us to begin our Phase 3 ...

It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic ...

today announced that its Phase I clinical trial of NEO212, a development-stage bio-conjugated therapeutic for brain cancer, is nearing full enrollment. The final cohort (Cohort 5) is expected to ...